Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population

Abstract

In order to determine the perception of general practitioners (GPs) and specialists regarding their clinical experience with the use of the low-dose fixed combination of perindopril 2 mg plus indapamide 0.625 mg in hypertensive patients with diabetes, a multicenter survey carried out across Spain was performed. A total of 894 physicians (597 GPs and 297 specialists) participated in the survey. A total of 5126 patients were included (3434 in the GPs’ group and 1692 in the specialists’ group). Associated risk factors and organ damage were more frequently documented in the specialists’ group. At baseline, 1.7% of the GPs’ patients and 1.3% of the specialists’ patients had their blood pressure controlled and with the combined therapy the blood pressure control rate attained 30.7 and 29.8%, respectively (p < 0.001 vs baseline and not significant intergroups). Less than 85% of physicians considered the efficacy and tolerability of combined therapy as ‘good’ or ‘very good’ but 93% of the patients were ‘satisfied’ or ‘very satisfied’ with combined therapy.

Keywords::

• combined therapy
• diabetes
• hypertension
• indapamide
• perindopril

Acknowledgements

The authors wish to express their most sincere and deepest gratitude to all investigators who have actively participated in this study. Without their dedication and quality of work the present publication would not have been possible. Unfortunately, the list of investigators is too long to be included in the publication.

Financial & competing interests disclosure

The present study was supported by an unrestricted grant from Servier, Spain. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.